2023 Fiscal Year Final Research Report
TWSG1, a BMP antagonist, could be a new therapeutic target in ovarian cancer.
| Project/Area Number |
22K20784
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0901:Oncology and related fields
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-08-31 – 2024-03-31
|
| Keywords | TWSG1 / BMP / がん幹細胞 / 細胞遊走 / EMT / がん抑制遺伝子 |
|---|
| Outline of Final Research Achievements |
Using ovarian cancer cell lines, we showed that TWSG1 inhibited both SMAD1/5/8 phosphorylation and mRNA expression of ID1 and SNAIL by BMP7. Furthermore, TWSG1 antagonized BMP7-induced enhancement of sphere formation and cell migration in sphere formation and cell migration assays. Thus, TWSG1 is a BMP7 antagonist and functions as a tumor suppressor gene. In the evaluation of clinical uterine cancer specimens, TWSG1 mRNA levels were significantly decreased in patients with vascular invasion and high grade cases.
|
| Free Research Field |
婦人科癌
|
| Academic Significance and Societal Importance of the Research Achievements |
卵巣癌は早期に腹腔内播種を引き起こす事が知られており、様々な分子標的治療が登場した現在でも難治性の悪性腫瘍である。我々の過去の報告から、BMP経路は卵巣癌の腹腔内播種を亢進させる可能性が示唆される。本研究ではTWSG1がBMP7に拮抗する事で、卵巣癌の腹腔内播種を抑制する可能性が示された。詳細なTWSG1の発現制御メカニズムを同定出来れば、卵巣癌患者に於いて、TWSG1の発現亢進を引き起こす事で卵巣癌の腹腔内播種をコントロールし、予後の改善に繋がる可能性があり、有望な新規分子標的治療になる事が期待される。
|
